MedTrace Logo

Impact of Hepatitis B Vaccination on HBs Antigenemia

NCT03193775 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2017-06-21

No results posted yet for this study

Summary

* HBV is not curable with persistent HBsAg even after the disappearance of HBV DNA.
* HBsAg \> 1000 IU/ml is associated with the risk of virological recurrence and HCC.
* There is an impaired immune response to HBsAg and HBV vaccine is an easily available, cost-effective, non-harmful method of stimulating immunity.

Conditions

  • HBV

Interventions

BIOLOGICAL

HBV vaccine

HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea) intramuscularly in deltoid region at three different time intervals (0, 1, 6 months).

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-01
Primary Completion
2015-10-01
Completion
2015-10-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193775 on ClinicalTrials.gov